<p>根据公司在最近向证券交易委员会提交的 13F 文件，Synovus Financial Corp 在第四季度将其在 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免费报告）中的持仓提高了 71.6%。该公司在本季度购买了 68,389 股后，持有 163,893 股这家生物技术公司的股票。到最近一个季度末，Synovus Financial Corp 大约拥有 Rocket Pharmaceuticals 0.18% 的股份，价值 2,060,000 美元。</p>
<p>获取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>3 只准备大幅上涨的小型股</li>
</ul>
<p>其他大型投资者最近也对该公司的持仓进行了调整。Covestor Ltd 在第四季度将其在 Rocket Pharmaceuticals 的股份提高了 33,166.7%。Covestor Ltd 现在拥有 1,996 股这家生物技术公司的股票，价值 25,000 美元，此前在上个季度又购买了 1,990 股。Kennedy Capital Management LLC 在第四季度将其在 Rocket Pharmaceuticals 的股份增加了 222.6%。Kennedy Capital Management LLC 现在拥有 38,208 股这家生物技术公司的股票，价值 480,000 美元，此前在此期间又收购了 26,365 股。Raymond James Financial Inc.在第四季度购买了 Rocket Pharmaceuticals 的新股份，价值 285,000 美元。Renaissance Technologies LLC 在第四季度购买了 Rocket Pharmaceuticals 的新股份，价值 2,747,000 美元。最后，Legal &amp; General Group Plc 在第四季度将其在 Rocket Pharmaceuticals 的股份提高了 3.3%。Legal &amp; General Group Plc 现在拥有 75,454 股这家生物技术公司的股票，价值 948,000 美元，此前在此期间又购买了 2,416 股。98.39% 的股票由机构投资者和对冲基金持有。</p>
<h2>Rocket Pharmaceuticals 股价上涨 10.5%</h2>
<p>NASDAQ:RCKT 周三开盘价为 6.53 美元。Rocket Pharmaceuticals, Inc.的 1 年最低价为 4.55 美元，1 年最高价为 26.98 美元。该公司的债务与股本比率为 0.06，速动比率为 6.05，流动比率为 6.05。该股票的 50 日移动平均价格为 8.19 美元，200 日移动平均价格为 11.92 美元。该股票的市值为 6.9629 亿美元，市盈率为-2.37，贝塔系数为 1.00。</p>
<p>Rocket Pharmaceuticals（NASDAQ:RCKT - 获取免费报告）最近在 3 月 3 日（星期一）发布了季度财报。这家生物技术公司报告的每股收益为（0.62 美元），超过分析师一致预期的（0.68 美元）0.06 美元。作为一个整体，卖方分析师预计 Rocket Pharmaceuticals, Inc.在当前财年将发布-2.83 的每股收益。</p>
<h2>Rocket Pharmaceuticals 的内部买卖</h2>
<p>在其他消息中，首席执行官 Gaurav Shah 在 4 月 10 日（星期四）购买了 20,000 股该股票。每股购买价格为 5.08 美元，总价值为 101,600.00 美元。收购完成后，首席执行官现在拥有 792,680 股该公司的股票，价值约为 4,026,814.40 美元。这笔交易代表了他们持股比例的 2.59% 的增加。该收购在向证券交易委员会的文件中披露，相关信息可通过此链接获取。此外，内部人士 Kinnari Patel 在 4 月 9 日（星期三）购买了 21,099 股该公司的股票。每股购买成本为 4.70 美元，总价值为 99,165.30 美元。购买后，该内部人士现在直接拥有 26,774 股该公司股票，价值约为 125,837.80 美元。这笔交易使他们的持股比例增加了 371.79%。该购买的披露信息可以在这里找到。目前 28.50% 的股票由公司内部人士持有。</p>
<h2>分析师的升级和降级</h2>
<p>多家研究公司对 RCKT 发表了评论。Chardan Capital 将 Rocket Pharmaceuticals 的股票目标价从 62.00 美元下调至 54.00 美元，并在 2 月 28 日（星期五）的研究报告中给予该股票 “买入” 评级。Jefferies Financial Group 在 12 月 18 日（星期三）的研究报告中开始覆盖 Rocket Pharmaceuticals。他们给予该公司 “买入” 评级，并设定 29.00 美元的目标价。Canaccord Genuity Group 在 3 月 3 日（星期一）的研究报告中将 Rocket Pharmaceuticals 的目标价从 39.00 美元下调至 36.00 美元，并给予该公司 “买入” 评级。Needham &amp; Company LLC 在 4 月 9 日（星期三）的报告中重申了 “买入” 评级，并对 Rocket Pharmaceuticals 的股票设定 42.00 美元的目标价。最后，BMO Capital Markets 在 3 月 12 日（星期三）的研究报告中开始覆盖 Rocket Pharmaceuticals。他们给予该公司 “跑赢大盘” 的评级，并设定 50.00 美元的目标价。一位分析师对该股票给予持有评级，十一位分析师给予该公司买入评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 43.00 美元。</p>
<p><strong>获取我们对 Rocket Pharmaceuticals 的最新分析</strong></p>
<h2>关于 Rocket Pharmaceuticals</h2>
<p>（免费报告）</p>
<p>Rocket Pharmaceuticals, Inc 及其子公司作为一家晚期生物技术公司，专注于开发针对罕见和严重疾病的基因疗法。它有三个临床阶段的外源性慢病毒载体项目，针对范可尼贫血，这是一种骨髓中的遗传缺陷，减少血细胞的产生或促进有缺陷血细胞的产生；白细胞粘附缺陷-I，这是一种导致免疫系统功能失常的遗传疾病；以及丙酮酸激酶缺乏症，这是一种罕见的红细胞常染色体隐性疾病，导致慢性非球形溶血性贫血。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Rocket Pharmaceuticals</li>
<li>标普 500 指数股票向投资者传达了什么市场信息？</li>
<li>当心 BigBear.ai：内部人士正在出售——你应该关注吗？</li>
<li>消费者可选类股票解析</li>
<li>随着网络威胁环境的扩大，CrowdStrike 股票值得购买</li>
<li>哪些华尔街分析师的准确性最高？</li>
<li>国会！在关税引发的崩溃中，谁交易了什么？</li>
</ul>
<p><strong>想看看其他对 RCKT 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com，获取 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资$1,000 在 Rocket Pharmaceuticals 吗？</h2>
<p>在考虑 Rocket Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Rocket Pharmaceuticals 并不在名单上。</p>
<p>虽然 Rocket Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Rocket制药

<p>根据 Synovus Financial Corp 最近向证券交易委员会提交的 13F 文件，该公司在 2023 年第四季度将其在 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免费报告）中的持仓提高了 71.6%</p>

<p>Synovus Financial Corp lifted its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 71.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 163,893 shares of the biotechnology company's stock after purchasing an additional 68,389 shares during the quarter. Synovus Financial Corp owned approximately 0.18% of Rocket Pharmaceuticals worth $2,060,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据公司在最近向证券交易委员会提交的 13F 文件，Synovus Financial Corp 在第四季度将其在 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免费报告）中的持仓提高了 71.6%。该公司在本季度购买了 68,389 股后，持有 163,893 股这家生物技术公司的股票。到最近一个季度末，Synovus Financial Corp 大约拥有 Rocket Pharmaceuticals 0.18% 的股份，价值 2,060,000 美元。</p>
</div><p>Get <strong>Rocket Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rocket Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>3 Small-Cap Stocks That Are Ready to Rocket Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只准备大幅上涨的小型股</li>
</ul>
</div><p>Other large investors have also recently made changes to their positions in the company. Covestor Ltd lifted its stake in Rocket Pharmaceuticals by 33,166.7% in the fourth quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock valued at $25,000 after buying an additional 1,990 shares during the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Rocket Pharmaceuticals by 222.6% in the 4th quarter. Kennedy Capital Management LLC now owns 38,208 shares of the biotechnology company's stock valued at $480,000 after acquiring an additional 26,365 shares during the period. Raymond James Financial Inc. purchased a new stake in Rocket Pharmaceuticals in the 4th quarter valued at $285,000. Renaissance Technologies LLC purchased a new stake in Rocket Pharmaceuticals in the 4th quarter valued at $2,747,000. Finally, Legal &amp; General Group Plc boosted its stake in Rocket Pharmaceuticals by 3.3% during the 4th quarter. Legal &amp; General Group Plc now owns 75,454 shares of the biotechnology company's stock worth $948,000 after purchasing an additional 2,416 shares during the period. 98.39% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投资者最近也对该公司的持仓进行了调整。Covestor Ltd 在第四季度将其在 Rocket Pharmaceuticals 的股份提高了 33,166.7%。Covestor Ltd 现在拥有 1,996 股这家生物技术公司的股票，价值 25,000 美元，此前在上个季度又购买了 1,990 股。Kennedy Capital Management LLC 在第四季度将其在 Rocket Pharmaceuticals 的股份增加了 222.6%。Kennedy Capital Management LLC 现在拥有 38,208 股这家生物技术公司的股票，价值 480,000 美元，此前在此期间又收购了 26,365 股。Raymond James Financial Inc.在第四季度购买了 Rocket Pharmaceuticals 的新股份，价值 285,000 美元。Renaissance Technologies LLC 在第四季度购买了 Rocket Pharmaceuticals 的新股份，价值 2,747,000 美元。最后，Legal &amp; General Group Plc 在第四季度将其在 Rocket Pharmaceuticals 的股份提高了 3.3%。Legal &amp; General Group Plc 现在拥有 75,454 股这家生物技术公司的股票，价值 948,000 美元，此前在此期间又购买了 2,416 股。98.39% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Rocket Pharmaceuticals Trading Up 10.5 %</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 股价上涨 10.5%</h2>
</div><p>NASDAQ:RCKT opened at $6.53 on Wednesday. Rocket Pharmaceuticals, Inc. has a 1 year low of $4.55 and a 1 year high of $26.98. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. The stock has a fifty day moving average price of $8.19 and a two-hundred day moving average price of $11.92. The stock has a market capitalization of $696.29 million, a price-to-earnings ratio of -2.37 and a beta of 1.00.</p>
<div class="lb-trans"><p>NASDAQ:RCKT 周三开盘价为 6.53 美元。Rocket Pharmaceuticals, Inc.的 1 年最低价为 4.55 美元，1 年最高价为 26.98 美元。该公司的债务与股本比率为 0.06，速动比率为 6.05，流动比率为 6.05。该股票的 50 日移动平均价格为 8.19 美元，200 日移动平均价格为 11.92 美元。该股票的市值为 6.9629 亿美元，市盈率为-2.37，贝塔系数为 1.00。</p>
</div><p>Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, topping analysts' consensus estimates of ($0.68) by $0.06. As a group, sell-side analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals（NASDAQ:RCKT - 获取免费报告）最近在 3 月 3 日（星期一）发布了季度财报。这家生物技术公司报告的每股收益为（0.62 美元），超过分析师一致预期的（0.68 美元）0.06 美元。作为一个整体，卖方分析师预计 Rocket Pharmaceuticals, Inc.在当前财年将发布-2.83 的每股收益。</p>
</div><h2>Insider Buying and Selling at Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rocket Pharmaceuticals 的内部买卖</h2>
</div><p>In other news, CEO Gaurav Shah bought 20,000 shares of the stock in a transaction on Thursday, April 10th. The shares were bought at an average price of $5.08 per share, with a total value of $101,600.00. Following the completion of the acquisition, the chief executive officer now owns 792,680 shares of the company's stock, valued at approximately $4,026,814.40. This trade represents a 2.59 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, insider Kinnari Patel purchased 21,099 shares of the business's stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average cost of $4.70 per share, with a total value of $99,165.30. Following the purchase, the insider now directly owns 26,774 shares in the company, valued at approximately $125,837.80. The trade was a 371.79 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 Gaurav Shah 在 4 月 10 日（星期四）购买了 20,000 股该股票。每股购买价格为 5.08 美元，总价值为 101,600.00 美元。收购完成后，首席执行官现在拥有 792,680 股该公司的股票，价值约为 4,026,814.40 美元。这笔交易代表了他们持股比例的 2.59% 的增加。该收购在向证券交易委员会的文件中披露，相关信息可通过此链接获取。此外，内部人士 Kinnari Patel 在 4 月 9 日（星期三）购买了 21,099 股该公司的股票。每股购买成本为 4.70 美元，总价值为 99,165.30 美元。购买后，该内部人士现在直接拥有 26,774 股该公司股票，价值约为 125,837.80 美元。这笔交易使他们的持股比例增加了 371.79%。该购买的披露信息可以在这里找到。目前 28.50% 的股票由公司内部人士持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师的升级和降级</h2>
</div><p>A number of research firms have commented on RCKT. Chardan Capital dropped their price objective on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, February 28th. Jefferies Financial Group started coverage on Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They set a &#34;buy&#34; rating and a $29.00 price objective for the company. Canaccord Genuity Group decreased their price objective on Rocket Pharmaceuticals from $39.00 to $36.00 and set a &#34;buy&#34; rating for the company in a research report on Monday, March 3rd. Needham &amp; Company LLC reissued a &#34;buy&#34; rating and issued a $42.00 target price on shares of Rocket Pharmaceuticals in a report on Wednesday, April 9th. Finally, BMO Capital Markets initiated coverage on Rocket Pharmaceuticals in a research note on Wednesday, March 12th. They set an &#34;outperform&#34; rating and a $50.00 price target for the company. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $43.00.</p>
<div class="lb-trans"><p>多家研究公司对 RCKT 发表了评论。Chardan Capital 将 Rocket Pharmaceuticals 的股票目标价从 62.00 美元下调至 54.00 美元，并在 2 月 28 日（星期五）的研究报告中给予该股票 “买入” 评级。Jefferies Financial Group 在 12 月 18 日（星期三）的研究报告中开始覆盖 Rocket Pharmaceuticals。他们给予该公司 “买入” 评级，并设定 29.00 美元的目标价。Canaccord Genuity Group 在 3 月 3 日（星期一）的研究报告中将 Rocket Pharmaceuticals 的目标价从 39.00 美元下调至 36.00 美元，并给予该公司 “买入” 评级。Needham &amp; Company LLC 在 4 月 9 日（星期三）的报告中重申了 “买入” 评级，并对 Rocket Pharmaceuticals 的股票设定 42.00 美元的目标价。最后，BMO Capital Markets 在 3 月 12 日（星期三）的研究报告中开始覆盖 Rocket Pharmaceuticals。他们给予该公司 “跑赢大盘” 的评级，并设定 50.00 美元的目标价。一位分析师对该股票给予持有评级，十一位分析师给予该公司买入评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，共识目标价为 43.00 美元。</p>
</div><p><strong>Get Our Latest Analysis on Rocket Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Rocket Pharmaceuticals 的最新分析</strong></p>
</div><h2>About Rocket Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Rocket Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.</p>
<div class="lb-trans"><p>Rocket Pharmaceuticals, Inc 及其子公司作为一家晚期生物技术公司，专注于开发针对罕见和严重疾病的基因疗法。它有三个临床阶段的外源性慢病毒载体项目，针对范可尼贫血，这是一种骨髓中的遗传缺陷，减少血细胞的产生或促进有缺陷血细胞的产生；白细胞粘附缺陷-I，这是一种导致免疫系统功能失常的遗传疾病；以及丙酮酸激酶缺乏症，这是一种罕见的红细胞常染色体隐性疾病，导致慢性非球形溶血性贫血。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Rocket Pharmaceuticals</li>
<li>What Do S&amp;P 500 Stocks Tell Investors About the Market?</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>Consumer Discretionary Stocks Explained</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Rocket Pharmaceuticals</li>
<li>标普 500 指数股票向投资者传达了什么市场信息？</li>
<li>当心 BigBear.ai：内部人士正在出售——你应该关注吗？</li>
<li>消费者可选类股票解析</li>
<li>随着网络威胁环境的扩大，CrowdStrike 股票值得购买</li>
<li>哪些华尔街分析师的准确性最高？</li>
<li>国会！在关税引发的崩溃中，谁交易了什么？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding RCKT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 RCKT 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com，获取 Rocket Pharmaceuticals, Inc.（NASDAQ:RCKT - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkNLVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RCKT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rocket Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Rocket Pharmaceuticals 吗？</h2>
</div><p>Before you consider Rocket Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Rocket Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Rocket Pharmaceuticals 并不在名单上。</p>
</div><p>While Rocket Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rocket Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Synovus Financial Corp

Rocket Pharmaceuticals, Inc.（纳斯达克代码：RCKT）的股份被 Synovus Financial Corp 收购